Treatment of Nontuberculous Mycobacterial (NTM) Pulmonary Infection in the US Bronchiectasis and NTM Registry: Treatment Patterns, Adverse Events, and Adherence to American Thoracic Society/Infectious Disease Society of America Treatment Guidelines

Among 1038 participants with pulmonary Mycobacterium avium complex and 120 with Mycobacterium abscessus enrolled in the US Bronchiectasis and NTM Research Registry, less than half received antibiotic therapy in the 24 months before registry enrollment, of which less than half were guideline based. A...

Full description

Saved in:
Bibliographic Details
Published inClinical infectious diseases Vol. 76; no. 2; pp. 338 - 341
Main Authors Ku, Jennifer H, Henkle, Emily, Aksamit, Timothy R, Barker, Alan, Brunton, Amanda E, Winthrop, Kevin L
Format Journal Article
LanguageEnglish
Published United States 13.01.2023
Subjects
Bronchiectasis - drug therapy
Communicable Diseases
Humans
Lung - microbiology
Lung Diseases - microbiology
Mycobacterium avium Complex
Mycobacterium Infections, Nontuberculous - drug therapy
Mycobacterium Infections, Nontuberculous - epidemiology
Mycobacterium Infections, Nontuberculous - microbiology
Nontuberculous Mycobacteria
Opportunistic Infections
adverse effects
Mycobacterium avium complex
antibiotic treatment
nontuberculous mycobacterial infection
Mycobacterium abscessus
Online AccessGet full text

Cover

More Information
Summary:Among 1038 participants with pulmonary Mycobacterium avium complex and 120 with Mycobacterium abscessus enrolled in the US Bronchiectasis and NTM Research Registry, less than half received antibiotic therapy in the 24 months before registry enrollment, of which less than half were guideline based. Adverse effects occurred in 21% of therapy recipients, of whom 33% discontinued therapy.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1058-4838
1537-6591
DOI:10.1093/cid/ciac788